Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | APEX1 | P27695 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MPI | P34949 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | SELL | P14151 | 1/20 | 0.52 |
| ▸ | SELP | P16109 | 1/20 | 0.52 |
| ▸ | SELE | P16581 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TPMT | P51580 | 4/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31090180 | 0.87 | PTPN1 (0.53) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| SCHEMBL658125 | 0.87 | PTPN1 (0.53) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| SCHEMBL8084791 | 0.87 | TDP1 (0.52) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| SCHEMBL29421895 | 0.85 | ACHE (0.70) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| SCHEMBL1427958 | 0.85 | ACHE (0.70) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| SCHEMBL11974268 | 0.80 | LMNA (0.48) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| Iretol SCHEMBL3190103 | 0.80 | TDP1 (1.00) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| SCHEMBL28064053 | 0.79 | ERN1 (0.58) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| SCHEMBL19034740 | 0.79 | ACHE (0.59) | TDP1MAPTALDH1A1KDM4EAPEX1 | |
| SCHEMBL4646583 | 0.78 | TDP1 (0.75) | TDP1MAPTALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2730565-B1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2017-04-26 | — | — | EP | disclosed |
| US-9139574-B2 | Tumor targeted drug combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| US-9139574-B2 | Tumor targeted drug combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| US-20150073045-A1 | POLYCYCLIC COMPOUNDS AND METHODS RELATED THERETO | CORNELL UNIVERSITY (US) | 2015-03-12 | — | — | US | disclosed |
| EP-2730565-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2014-05-14 | — | — | EP | disclosed |
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-8563603-B2 | Polycyclic compounds and methods related thereto | CORNELL UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2013004075-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | 南京圣和药业有限公司 (CN) | 2013-01-10 | — | — | WO | disclosed |
| EP-2479203-A1 | AROMATIC POLYESTER | Muroran Institute of Technology (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172570-A1 | AROMATIC POLYESTER | NITTA CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-8129493-B2 | Aromatic polyester | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110275708-A1 | POLYCYCLIC COMPOUNDS AND METHODS RELATED THERETO | CORNELL UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110092662-A1 | AROMATIC POLYESTER | NITTA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-1067109-B1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073045-A1 | POLYCYCLIC COMPOUNDS AND METHODS RELATED THERETO | PKD1, THPO, CCNO | TDP1 1420/4885MAPT 3462/4885ALDH1A1 1263/4885 |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | F12, PHAX, WDR82 | TDP1 3534/4885MAPT 1923/4885ALDH1A1 1882/4885 |
| US-20110275708-A1 | POLYCYCLIC COMPOUNDS AND METHODS RELATED THERETO | PKD1, THPO, CCNO | TDP1 1074/4885MAPT 3680/4885ALDH1A1 842/4885 |
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | TUBA4A, TUBGCP4, TUBB4A | TDP1 1914/4885MAPT 162/4885ALDH1A1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.